CANADA – bioMérieux, a global pioneer in vitro diagnostics, has announced the purchase of LUMED, a software firm that has developed a clinical decision support system to assist hospitals in optimizing antibiotic prescriptions and monitoring healthcare-associated infections.

Following this acquisition, bioMérieux now owns 100% of Canadian innovative software startup LUMED, raising its shareholding from 16% to 100%.

The two companies have been collaborating closely since 2017, and this acquisition of 84% of the capital signifies an approximately 9 million-euro investment.

Appropriate data utilization is critical for hospitals to offer safe and appropriate patient care while controlling pharmacy costs.

LUMED’s innovative software solutions assist in ensuring that local antimicrobial prescribing criteria are followed and enforced.

It also provides healthcare professionals with all of the varied and relevant information they need to optimize their Antimicrobial Stewardship Programs (ASP) and Infection Prevention and Control (IPC) programs in order to provide better care for their patients, combat AMR, and improve infection control.

Diagnostic and other crucial data collected all along the healthcare pathway, when examined by intelligent software, are critical in supporting various health professionals in their decision-making process, resulting in optimal advantages for patients.

LUMED’s products are an ideal complement to bioMérieux’s comprehensive range of software solutions, BIOMÉRIEUX VISION SUITE.

BIOMÉRIEUX VISION SUITE collects and organizes laboratory and hospital data into relevant and actionable information.

This serves to assist diagnostic and clinical decisions at all levels, from individual patient care to public health surveillance, in order to prevent antimicrobial resistance and promote antimicrobial stewardship.

Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux, stated during the announcement that this acquisition will expand the reach of diagnostic testing beyond the laboratory.

Many hospitals around the world, according to her, are organizing themselves around the major challenges of antimicrobial resistance and infection control.

She expressed optimism that, with LUMED on board, the company will provide solutions for antimicrobial stewardship teams to better their daily workflow, as the software will contribute to streamlining the process of care delivery as well as expenses and patient management.

On his part, Vincent Nault, Chief Executive Officer of LUMED, stated that this acquisition represents a significant milestone in their journey and that by collaborating with bioMérieux, LUMED is committed to advancing antimicrobial stewardship and infection prevention through cutting-edge modules such as APSS and ZINC.

He went on to remark that by integrating LUMED’s revolutionary software solutions with bioMérieux’s global reach and diagnostic expertise, a significant synergy will be created.

According to Nault, this will improve patient care, combat antibiotic resistance, and contribute to the evolution of healthcare practices.

This acquisition of LUMED demonstrates bioMérieux’s willingness to expand its Data Analytics portfolio while maintaining a focus and commitment to antimicrobial stewardship and infection prevention and control.

bioMérieux is excited to welcome the LUMED team and begin leveraging its global commercial network to provide the benefits of LUMED software to as many patients as possible.

Since 1963, bioMérieux has been a global pioneer in the field of in vitro diagnostics, with a presence in 45 countries and a wide network of distributors serving more than 160 nations.

bioMérieux’s revenues reached €3.6 billion in 2022, with more than 90% of sales occurring outside of France.

The company offers diagnostic solutions such as systems, reagents, software, and services to establish the cause of disease and contamination in order to improve patient health and consumer safety.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.